<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30464629</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1179-1322</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Cancer management and research</Title>                <ISOAbbreviation>Cancer Manag Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study.</ArticleTitle>            <Pagination>                <MedlinePgn>5329-5338</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CMAR.S176763</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">It was unclear whether breast cancer subtypes are associated with the risk of site-specific metastases. This study aimed to evaluate the relationship between molecular subtypes and distant metastatic sites and their prognostic significance.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We identified 295,213 patients with invasive breast cancer from 2010 to 2014 using the Surveillance, Epidemiology and End Results database. Subtypes were classified into four categories: hormone receptor (HR<sup>+</sup>)/human epidermal growth factor receptor 2 (HER2<sup>-</sup>), HR<sup>+</sup>/HER2<sup>+</sup>, HR<sup>-</sup>/HER2<sup>+</sup>, and triple-negative (HR<sup>-</sup>/HER2<sup>-</sup>). Logistic regression was used to assess the association between metastasis location and subtypes. Multivariate Cox models were used to estimate the overall survival (OS) of related factors.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">According to our study, 3.28%, 1.52%, 1.20%, and 0.35% of newly diagnosed breast cancers presented bone, lung, liver, and brain metastases at diagnosis, respectively. Both metastatic sites and subtypes significantly affected the OS after metastasis. In multivariate analysis, HR<sup>+</sup>/HER2<sup>+</sup> subtype (OR as compared with HR<sup>+</sup>/HER2<sup>-</sup> subtype, 1.30 [95% CI, 1.22-1.39]) significantly correlated with elevated bone metastasis risk, whereas HR<sup>-</sup>/HER2<sup>+</sup> did not. Both HER2<sup>+</sup> subtypes (HR<sup>+</sup>/HER2<sup>+</sup> and HR<sup>-</sup>/HER2<sup>+</sup>) were significantly associated with higher rates of liver, brain, and lung metastases, while the highest OR was observed in liver metastases. Triple-negative tumors had a higher rate of brain (OR, 1.95 [95% CI, 1.61-2.35]), liver (OR, 1.35 [95% CI, 1.20-1.51]), and lung metastases (OR, 1.34 [95% CI, 1.21-1.47]), but a significantly lower rate of bone metastases (OR, 0.64 [95% CI, 0.59-0.69]) than HR<sup>+</sup>/HER2-tumors.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Breast cancer subtypes are associated with different metastatic patterns and confer different prognostic impacts. Molecular subtypes can identify patients at increased risk of site-specific metastases.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Xiao</LastName>                    <ForeName>Weikai</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People's Republic of China, tanghl@sysucc.org.cn; xiexm@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zheng</LastName>                    <ForeName>Shaoquan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People's Republic of China, tanghl@sysucc.org.cn; xiexm@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Anli</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine; Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Xingcai</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Applied Physics, Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA 02138, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zou</LastName>                    <ForeName>Yutian</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People's Republic of China, tanghl@sysucc.org.cn; xiexm@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tang</LastName>                    <ForeName>Hailin</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People's Republic of China, tanghl@sysucc.org.cn; xiexm@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Xiaoming</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People's Republic of China, tanghl@sysucc.org.cn; xiexm@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Cancer Manag Res</MedlineTA>            <NlmUniqueID>101512700</NlmUniqueID>            <ISSNLinking>1179-1322</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">metastasis behavior</Keyword>            <Keyword MajorTopicYN="N">metastatic sites</Keyword>            <Keyword MajorTopicYN="N">molecular subtypes</Keyword>            <Keyword MajorTopicYN="N">prognosis</Keyword>        </KeywordList>        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30464629</ArticleId>            <ArticleId IdType="doi">10.2147/CMAR.S176763</ArticleId>            <ArticleId IdType="pii">cmar-10-5329</ArticleId>            <ArticleId IdType="pmc">PMC6225920</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>